Elevance Health Inc

Elevance Health Inc(ELV)股票分析

$428.090

+2.825 (+0.66%)收盤時

Loading chart…
最高
434.000
開盤
428.820
成交量加權均價
427.96
成交量
2.12M
市值
124.52B
最低
421.780
成交金額
905.64M
企業價值/稅息折舊攤銷前利潤(TTM)
10.62

Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to its Individual, Employer Group risk-based, Employer Group fee-based, BlueCard, Medicare, Medicaid and Federal Employee Program (FEP) members. The Health Benefits segment also offers health products on a full-risk basis. The CarelonRx segment includes its pharmacy services business. CarelonRx markets and offers pharmacy services to its affiliated health plan customers, as well as to external customers outside of the health plans. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services by offering an array of healthcare-related services and capabilities to internal and external customers through its Carelon Health and Carelon Insights businesses.

AI 分析 of Elevance Health Inc (ELV)

買進

Elevance Health Inc is a good buy right now due to its current price of $412.7 being below the analyst price target of $480 from BofA, indicating a potential upside of 16.3%. Additionally, the stock's RSI of 71.921 suggests it is nearing overbought territory, but the strong earnings performance with a 20.55% EPS surprise last quarter supports continued growth. The main risk is the hedge fund selling trend, which has increased by 135.25% over the last quarter, indicating potential bearish sentiment among institutional investors.

估值指標

Elevance Health Inc(ELV)目前預期本益比為 13.68,5 年平均預期本益比為 13.76。

預期本益比

合理
5 年均值 P/E
13.76
目前P/E
13.68
高估
15.58
低估
11.94

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
10.29
目前EV/EBITDA
10.62
高估
11.86
低估
8.73

預期股價營收比

合理
5 年均值 P/S
0.58
目前P/S
0.46
高估
0.72
低估
0.44

Alphio AI 對 ELV 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%ELV

$456.04

情境價格

基

基準

基準 · 50%ELV

$450.58

情境價格

悲

悲觀

悲觀 · 25%ELV

$379.11

情境價格

持有 ELV 的大戶

A

ARGA Investment Management, LLC

+ 持有ELV

+12.89%

3個月報酬率

G

Grantham Mayo Van Otterloo & Co. LLC

+ 持有ELV

+7.80%

3個月報酬率

S

Sanders Capital, LLC

+ 持有ELV

+7.60%

3個月報酬率

T

Trajan Wealth, L.L.C.

+ 持有ELV

+6.51%

3個月報酬率

Y

Yacktman Asset Management LP

+ 持有ELV

+5.83%

3個月報酬率

M

Manulife Asset Management

+ 持有ELV

+5.55%

3個月報酬率

ELV 常見問題 —— 由 Alphio AI 解答

Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to its Individual, Employer Group risk-based, Employer Group fee-based, BlueCard, Medicare, Medicaid and Federal Employee Program (FEP) members. The Health Benefits segment also offers health products on a full-risk basis. The CarelonRx segment includes its pharmacy services business. CarelonRx markets and offers pharmacy services to its affiliated health plan customers, as well as to external customers outside of the health plans. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services by offering an array of healthcare-related services and capabilities to internal and external customers through its Carelon Health and Carelon Insights businesses. It operates in the Healthcare sector (HOSPITAL & MEDICAL SERVICE PLANS industry).

Elevance Health Inc is a good buy right now due to its current price of $412.7 being below the analyst price target of $480 from BofA, indicating a potential upside of 16.3%. Additionally, the stock's RSI of 71.921 suggests it is nearing overbought territory, but the strong earnings performance with a 20.55% EPS surprise last quarter supports continued growth. The main risk is the hedge fund selling trend, which has increased by 135.25% over the last quarter, indicating potential bearish sentiment among institutional investors.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易